Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT0918 (Proxalutamide) in mHSPC and mCRPC
NCT03899467Phase 2Completed
- Sponsor
- Kintor Pharmaceutical Limited
- Start
- May 2019
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of proxalutamide in metastatic castration-resistant prostate cancer (mCRPC), prostate cancer (PCa), sponsored by Kintor Pharmaceutical Limited. Started May 2019; status: completed.
02
Drugs
proxalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03899467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03899467.